The focus of future research work in this area may also concentrate on establishing the selective inhibitors of immunoproteasome subunits LMP2 and LMP7 to eliminate the progression of the disease and recurrent or residual cholesteatoma cases. Here, PSMB9 is linked to cholesteatoma.